Mail

UK markets closed

FTSE 100
8,213.49
+41.34(+0.51%)
FTSE 250
20,164.54
+112.21(+0.56%)
AIM
771.53
+3.42(+0.45%)
GBP/EUR
1.1656
-0.0027(-0.23%)
GBP/USD
1.2544
+0.0011(+0.09%)
Bitcoin GBP
49,248.52
+2,029.89(+4.30%)

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

Day One Biopharmaceuticals, Inc. (DAWN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

17.28

-0.29

(-1.65%)

As of 01:17PM EDT. Market open.

Currency in USD

Valuation measures⁴

Market cap (intra-day)	1.54B
Enterprise value	1.17B
Trailing P/E	N/A
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	N/A
Price/book (mrq)	4.43
Enterprise value/revenue	N/A
Enterprise value/EBITDA	-5.68

Trading information

Stock price history

Beta (5Y monthly)	-1.48
52-week change ³	28.44%
S&P500 52-week change ³	22.43%
52-week high ³	18.07
52-week low ³	9.67
50-day moving average ³	15.37
200-day moving average ³	13.67

Share statistics

Avg vol (3-month) ³	1.03M
Avg vol (10-day) ³	2.67M
Shares outstanding ⁵	87.38M
Implied shares outstanding ⁶	100.47M
Float ⁸	54.61M
% held by insiders ¹	19.85%
% held by institutions ¹	89.23%
Shares short (15 Apr 2024) ⁴	8.94M
Short ratio (15 Apr 2024) ⁴	11.1
Short % of float (15 Apr 2024) ⁴	12.77%
Short % of shares outstanding (15 Apr 2024) ⁴	10.23%
Shares short (prior month 15 Mar 2024) ⁴	9.61M

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	N/A
Ex-dividend date ⁴	N/A
Last split factor ²	N/A
Last split date ³	N/A

Financial highlights

Fiscal year

Fiscal year ends	31 Dec 2023
Most-recent quarter (mrq)	31 Dec 2023

Profitability

Profit margin	0.00%
Operating margin (ttm)	0.00%

Management effectiveness

Return on assets (ttm)	-35.52%
Return on equity (ttm)	-55.68%

Income statement

Revenue (ttm)	N/A
Revenue per share (ttm)	N/A
Quarterly revenue growth (yoy)	N/A
Gross profit (ttm)	N/A
EBITDA	-206.03M
Net income avi to common (ttm)	-188.92M
Diluted EPS (ttm)	-2.37
Quarterly earnings growth (yoy)	N/A

Balance sheet

Total cash (mrq)	366.35M
Total cash per share (mrq)	4.19
Total debt (mrq)	408k
Total debt/equity (mrq)	0.12%
Current ratio (mrq)	12.72
Book value per share (mrq)	3.97

Cash flow statement

Operating cash flow (ttm)	-146.85M
Levered free cash flow (ttm)	-82.72M